I think it’s, as we’ve seen even at the study, that oral SERDs are showing efficacy and a role in the early stage setting, which is super exciting. We saw from the lidERA trial at this meeting that oral SERDs were superior to standard endocrine therapy. And I think there is no better place to study endocrine therapy, especially in early staging, than in the neoadjuvant setting, right? To understand who are the patients that benefit the most, who are the patients who may not stand to benefit, How do we study combinations? And looking, even in early development of these agents, looking for biomarkers of mechanisms of activity, of resistance, there’s no better place than a neoadjuvant setting...
I think it’s, as we’ve seen even at the study, that oral SERDs are showing efficacy and a role in the early stage setting, which is super exciting. We saw from the lidERA trial at this meeting that oral SERDs were superior to standard endocrine therapy. And I think there is no better place to study endocrine therapy, especially in early staging, than in the neoadjuvant setting, right? To understand who are the patients that benefit the most, who are the patients who may not stand to benefit, How do we study combinations? And looking, even in early development of these agents, looking for biomarkers of mechanisms of activity, of resistance, there’s no better place than a neoadjuvant setting. So I think as we develop agents for breast cancer, which, you know, whether that’s in the metastatic setting or in the adjuvant setting, it is very valuable to also test them in the neoadjuvant setting to look for those signals and be able to get some early readouts and better understanding of the drug’s mechanisms.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
